{name}
{subtitle}
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
city
~31 mi. (Kryvyi Rih, Ukraine, +89 more cities)
facility
Medical Center of LLC Mriya Med-Service
biomarker
ER Positive, +1 more biomarker
drug
giredestrant, +1 more drug
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~31 mi. (Kryvyi Rih, Ukraine, +192 more cities)
facility
MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council; Chemotherapy Department
biomarker
ER Positive, +1 more biomarker
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003)
city
~31 mi. (Kryvyi Rih, Ukraine, +93 more cities)
facility
MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional-Chemotherapy department ( Site 1104)
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
city
~31 mi. (Kryvyi Rih, Ukraine, +67 more cities)
facility
Medical Center Mriya Med-Service ( Site 1805)
drug
carboplatin, +5 more drugs
drug type
chemotherapy, +1 more type
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
city
~31 mi. (Kryvyi Rih, Ukraine, +62 more cities)
facility
2807--Dniprovske shose
biomarker
ER Negative, +2 more biomarkers
drug
carboplatin, +2 more drugs
drug type
chemotherapy, +1 more type